Previsioni

Acquista	1
Mantieni	2
Vendi	0

Notizie Vai al feed delle notizie

Mainz Biomed to be renamed Quantum Cyber and appoints Robert P. Liscouski as chairman

Mainz Biomed announces a strategic reorientation: the company will change its name to Quantum Cyber and will use the NASDAQ ticker symbol QUCY starting Thursday. Robert P. Liscouski has been appointed chairman of the board; the measures are to take effect at an extraordinary general meeting in April. The reorientation follows ongoing financial difficulties, with a share price of $0.83, a market capitalization of $8.93 million and a weak Financial Health Score, while the company plans to continue developing its pancreatic screening offering and to evaluate other assets. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Mainz Biomed B.V. ha registrato ricavi pari a 0,00€ e un utile netto di −9,65M€

(EUR)	giu 2026	YoY
Ricavi	0,00	-
Utile lordo	0,00	-
Utile netto	−9,65M	-
EBITDA	−8,66M	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+12,62M€
Numero di azioni	4,09M
Massimo/minimo a 52 settimane	+4,59€ - +0,47€
Dividendi	No
Beta	0,32
Rapporto P/E	−0,73
Rapporto PEG	+0,01
Rapporto P/B	+1,30
Rapporto P/S	+123,68

Profilo aziendale

Mainz Biomed B.V., ein molekulargenetisches Krebsdiagnoseunternehmen, entwickelt In-vitro-Diagnosetests (IVD) und reine Forschungstests für die klinische Diagnostik in der Humangenetik. Das Unternehmen bietet ColoAlert, einen Screening-Test für Darmkrebs, PancAlert, einen Produktkandidaten für einen Screening-Test für Bauchspeicheldrüsenkrebs, GenoStrip zum Nachweis von Krankheitserregern in der Umwelt auf molekulargenetischer Basis sowie IVD-Tests für Forschungszwecke an. Das Unternehmen wurde 2008 gegründet und hat seinen Sitz in Mainz, Deutschland.

Nome	Mainz Biomed B.V.
CEO	Guido Baechler
Sede centrale	Mainz, Germania
Sito web	mainzbiomed.com
Settore	Sanità
Industria	Biotecnologia
Quotazione in borsa	05/11/2021
Dipendenti	19